



Prepared on February 27, 2023

Kenneth Paul Olive, Ph.D.

1130 St. Nicholas Ave
ICRC Bldg, Room 208E
New York, NY 10032
212-851-4678
kenolive@columbia.edu

Birthplace Ridgewood, NJ
Citizenship USA

Academic Appointments:

04/2022 – present Co-leader, Precision Oncology and Systems Biology Program, HICCC
06/2020 – 1/2022 COVID19 Research Ramp-up Ambassador, Schools of Medicine, Nursing, and Public Health
08/2019 – present Director of GI Translational Research, Department of Medicine, Division of Digestive and Liver Disease
04/2019 – present Associate Professor with Tenure, Division of Digestive and Liver Diseases, Department of Medicine, Columbia University Medical Center
08/2017 – present Director, Oncology Precision Therapeutics Imaging Core, Herbert Irving Comprehensive Cancer Center (HICCC)
03/2012 – 08/2017 Director, Small Animal Imaging Shared Resource, HICCC
01/2010 – 07/2019 Assistant Professor, Departments of Medicine, Division of Digestive and Liver Diseases
01/2010 – present Member, Columbia University Herbert Irving Comprehensive Cancer Center
01/2010 – 11/2018 Assistant Professor, Department of Pathology and Cell Biology

Education

09/1998 – 01/2005 **Ph.D. Biology, Massachusetts Institute of Technology**
Sponsor: Prof. Tyler Jacks
Thesis: “The Germline– and Tissue–Specific Effects of Endogenous Point-Mutant p53”
Citations: Olive et. al, **Cell**, Vol. 119, 847–860, 2004
 Jackson & Olive et. al, **Cancer Research**, 65(22): 10280-10288, 2005

09/1994 – 05/1998 **B.S. Biology, Bucknell University**
Department of Biology, Magna Cum Laude, with Honors
Sponsor: Mitchell Chernin
Thesis: “Increased c-myc protooncogene expression in mouse bone cells transfected with a fragment of the chicken c-myc gene: induction of a tumorigenic phenotype”

Training

09/2006 – 12/2009 **Postdoctoral Fellowship, Cambridge Research Institute/University of Cambridge**
Advisor: David Tuveson, pancreatic cancer translational therapeutics

01/2005 – 08/2006 **Postdoctoral Fellowship, University of Pennsylvania**
Advisor: David Tuveson, pancreatic cancer translational therapeutics

Honors and Awards

2019 Awarded tenure at Columbia University
2015 Ruth Siegel Prize for Excellence in Pancreatic Cancer Research (Columbia University)
2014 Subject of Feature article: “The Littlest Patient”, **Science**, J. Couzin-Frankel, 346: 24-27
2009 AACR Scholar-in-Training Award, MMHCC Meeting, San Francisco.

2006 – 2009 NIH Ruth L. Kirschstein National Research Service Awards, Postdoctoral Fellowship
2006 AACR Scholar-in-Training Award, Gerald B. Grindey Memorial Fund
2003 – 2004 Koch Graduate Fellowship in Cancer Research
1998 John T. Lowry Jr. Prize, most outstanding graduate, Dept. of Biology, Bucknell University

Academic Service

2020 – present Speaker at annual event on Mentoring and Mentorship, for the Responsible and Ethical Conduct of Research series held by the Office of Research Compliance and Training.
2017 – present Established and directs the HICCC Oncology Precision Therapeutics Imaging Core (OPTIC)
2010 – present The Pancreas Center, Executive Committee
2010 – present Interviewing for graduate programs (Pathobiology, Integrated CMBS, Pharmacology, and MD/PhD), performing 10 – 20 interviews per year
2020 Faculty advisor to Columbia Researcher Against COVID19 (CRAC Teams), which organized the emergency response efforts of >750 volunteers at the start of the pandemic.
2016 – 2018 Reviewer, Irving Institute Pilot Award and Educational Programs
2015 Established the small animal MRI service for HICCC
2012 – 2014 Institutional Animal Care and Use Committee (IACUC)
2011 – 2012 Pancreas SPORE Organizing Committee
2011 Established Small Animal Imaging Shared Resource within HICCC

Conference Organization

2019 Principal organizer, “2019 Gigi Shaw Arledge Symposium on Pancreatic Disease”, Columbia University, New York, NY
2017 Principal organizer, “2017 Gigi Shaw Arledge Symposium on Pancreatic Disease”, Columbia University, New York, NY
2015 Principal organizer, “2015 Gigi Shaw Arledge Symposium on Pancreatic Disease”, Columbia University, New York, NY
2014 Principal organizer, New York Academy of Sciences Symposium, "Pancreatic cancer: targeting key vulnerabilities", New York, NY
2013 Principal organizer, “2013 Gigi Shaw Arledge Symposium on Pancreatic Disease”, Columbia University, New York, NY
2012 Organizer, New York Academy of Sciences Symposium: “Phosphatidylserine asymmetry and Cell Survival: Therapeutic Applications in Cancer and Infectious Disease”, New York, NY
2012 Organizer, New York Academy of Sciences Symposium: “Targeting hypoxia for cancer imaging and therapy”, New York, NY
2012 Principal organizer, “Pancreatic cancer: translating new ideas”, New York, NY
2011 Principal organizer, “2011 Gigi Shaw Arledge Symposium on Pancreatic Disease”, Columbia University, New York, NY

Professional Organizations, Societies, and Service

Memberships and Positions

2010 – present Member, American Association for Cancer Research
2010 – 2015 Member, New York Academy of Sciences Cancer Signaling Discussion Group
2010 – 2013 Member, American Gastroenterological Association
2005 – 2009 Associate Member, American Association for Cancer Research

Consultative

2022 NIH Study Section, Ad Hoc: SEP-4 NCI Clinical and Translational Cancer Research
NIH Study Section, Ad Hoc: ZCA1 TCRB-V (M1)
2020 NIH Study Section, Ad Hoc: CAMP

2019	NIH Study Section, Ad Hoc: NIDDK GI
2017	NIH Study Section, Ad Hoc: ZRG1 BMCT-C
2016 – present	Scientific Advisory Board, Elstar Therapeutics
2015	NIH Study Section, Ad Hoc: Cancer Genetics
2013	NIH Study Section, F09 Fellowship: Oncological Sciences
2012 – 2015	Scientific Advisory Board, Lustgarten Foundation for Cancer Research
2012	NIH Study Section, ZRG1 BMCT-C(09)

Journal Reviews

2022	Nature, Cancer Discovery, Nature Communications
2021	Nature, Nature Cancer
2020	Nature, Cancer Discovery, Nature Communications, Elife
2019	PNAS, Scientific Reports, Clinical Cancer Research, Cancer Research
2018	Nature, Nature Communications
2017	Nature, Cancer Cell (2), Carcinogenesis
2016	Science, Cancer Cell, Clinical Cancer Research
2015	Nature Communications, Cell, Nature Medicine
2014	Nature (2), Nature Medicine, Cancer Cell, Clinical Cancer Research
2013	Nature (2)
2012	Oncogene, PNAS
2011	Clinical Cancer Research, Oncogene, European Journal of Cancer
2010	Science Translational Medicine, Clinical Cancer Research, J. Hepatology, J. Cell Science

Fellowship and Grant Support*Present support*

R01CA266558 NIH/NCI	Olive (PI)	12/01/2022 – 11/30/2027	2.4 months
“Targeting cell regulatory states to complement MEK/autophagy inhibition in pancreatic cancer”			
1U01CA274312-01 NIH/NCI	Olive (PI)	07/01/2022 – 06/30/2027	2.4 months
“Elucidation and targeting of paracrine cascades in PDAC”			
1P30 DK132710-01 NIH/NIDDK	Schwabe (PI)	01/01/2022 – 12/31/2027	0.75 months
The Columbia University Digestive and Liver Disease Research Center			
Revolution Medicine Sponsored Research Agreement	Olive (PI)	12/13/2021 – 12/12/2024	1.2 months \$197,000 Annual Direct
“Translational studies of mutant Ras inhibition in models of pancreatic ductal adenocarcinoma”			
5R01CA256840-02 NIH	Admundson (PI)	01/01/2021 – 12/31/2025	0.45 months
Linear energy transfer (LET) dependencies for understanding pancreatic tumor control and relevant molecular endpoints in support of RBE-based heavy-ion radiotherapy			
Pancreatic Cancer Action Network Translational research grant	Olive (PI)	07/01/2020 - 06/30/2023	2.4 months \$250,000 Annual Direct
Therapeutic induction of tumor selective ferroptosis in pancreatic cancer			

Philanthropic Donation 06/01/2021 - 05/31/2024
Foote Foundation

A \$375,000 gift over 3 years to fund research in the Olive Laboratory

Translational Clinical Program Olive (PI) 02/01/2018 – 10/31/2022 2.4 months
Lustgarten Foundation for Pancreatic Cancer Research \$2,230,654 total direct

“Clinical translation of regulatory network-based precision medicine for pancreatic cancer”

This program-level grant will support a clinical trial of network-based precision medicine for pancreatic cancer as well as a complementary preclinical research effort to develop combination therapies.

2R01 NCI 2R01CA215607-06 Olive (PI) 03/11/2022 – 02/28/2027 2.4 months
NIH/NCI \$252,858 annual direct

“Targeting cysteine import to induce ferroptotic cell death in pancreatic cancer”

Metabolism experiments designed to explore the function of cysteine in pancreatic cancer and its relationship to ferroptosis (an ROS-mediated cell death), using cell culture, metabolomics, and mouse models.

Past Support

2R01 NCI 1R01CA215607-01 Olive (PI) 03/01/2017 – 02/28/2022 2.4 months
NIH/NCI \$252,858 annual direct

“Targeting cysteine import to induce ferroptotic cell death in pancreatic cancer”

Metabolism experiments designed to explore the function of cysteine in pancreatic cancer and its relationship to ferroptosis (an ROS-mediated cell death), using cell culture, metabolomics, and mouse models.

1U54CA209997-01 Califano (Co-Inv.) 08/08/2016 – 07/31/2021 0.6 months
NIH/NCI \$41,121 of \$1,244,907 annual direct

“Centers for Cancer Systems Therapeutics (CaST)”

This subaward will fund systems biology investigations into the cellular heterogeneity of pancreatic cancer.

Philanthropic Donation 06/01/2020 - 05/31/2021
Foote Foundation

A \$875,000 gift over 1 year to fund precision medicine research in the Olive Laboratory.

IION Award Olive (PI) 09/01/2017 – 02/16/2021 2.4 months
Bristol Meyers Squibb \$422,685 total direct

“Parsing local immunosuppression in pancreatic ductal adenocarcinoma”

A computational analysis of pancreatic tumors combined with immunophenotyping of cellular populations across a large cohort of human PDA cases.

NCI 3 P30 CA13696-40 Emerson (Core Director) 07/01/2014 - 06/30/2019 0.92 months
NIH/NCI Role: Director, Small Animal Imaging SR \$183,795 total direct (core)

This Cancer Center Support Grant provides support for the Herbert Irving Comprehensive Cancer Center, and specifically to the Small Animal Imaging Shared Resource.

CCSG Administrative Supp. Olive (PI) 10/01/2016 – 09/31/2018 2.4 months
NIH/NCI \$315,000 total direct

“Combination targeting of fibroblast and myeloid populations to improve immune responses in pancreatic cancer”.

This study will use both systems and experimental biology approaches to study the interactions of cancer associated fibroblasts and myeloid cells in the pancreatic cancer stroma. These populations will be targeted therapeutically to increase CD8 T-cell responses in pancreatic cancer.

Sponsored Research Project **Olive** **(PI)** 12/01/2014 – 10/31/2017 0.6 months
Merck Oncology \$357,143 total direct

“Preclinical evaluation of PD-1 inhibitor combinations in pancreatic cancer”

This study will evaluate combinations of PD-1, AMD3100, and gemcitabine in a genetically engineered mouse model of pancreatic cancer.

Imaging RFA **Olive** **(PI)** 08/01/2013 – 07/31/2017 1.2 months
Lustgarten Foundation (No cost extension) \$1,066,962 total direct

“Focused Ultrasound Technologies for Diagnosis, Monitoring, and Treatment of Pancreatic Cancer”

Preclinical development and clinical translation of a novel functional ultrasound technology for pancreatic cancer. Collaboration with Dr. Elisa Konofagou, Dept. of Biomedical Engineering.

Philanthropic donation 12/31/2014 - 12/30/2016
Sue Mirza

A \$225,000 gift to the Pancreas Center for the purpose of funding a genomic medicine project in the Olive laboratory.

Precision Medicine Pilot Grant **Olive** **(PI)** 02/01/2016 – 01/31/2017 0.36 months
Irving Institute for Clinical and Translational Research \$100,000 total direct

“Precision targeting of pancreatic cancer regulatory networks”

This study will perform perturbation analysis of pancreatic tumor cells to identify agents and combinations that inhibit the activity of pancreatic cancer master regulator proteins that were identified in a large-scale systems biology project in our lab.

1R01CA157980-01 **Olive** **(PI)** 03/01/2011 – 12/31/2016 2.4 months
NIH/NCI Parent R01 (No cost extension) \$1,037,500 total direct

“Mechanisms of the Stromal Response to Smoothed Inhibition in Pancreatic Cancer”

The goal of this proposal is to investigate the molecular mechanisms of observed changes in the stroma of pancreatic tumors following treatment with Hedgehog pathway inhibitors.

122801 **Olive** **(PI)** 07/01/2012 – 06/30/2016 1.2 months
American Cancer Society \$800,000 total direct

“Preclinical Evaluation of Parp Inhibition in Pancreatic Cancer”

The goal of this proposal is to evaluate a Parp inhibitor in the context of BRCA2 wild type and deficient pancreatic tumors to determine sensitivity, and to identify biomarkers of resistance versus sensitivity.

1 U54 CA163111-01 **Wang** **(Co-Inv.)** 09/22/2011 – 07/31/2016 0.6 months
NIH/NCI Interdisciplinary Research Consortium Olive: \$32,500 total direct

"Myofibroblasts in Gastrointestinal Cancers"

The focus of this project is to study the role of myofibroblasts in gastric and pancreatic cancer. Our role in this cooperative effort is to execute a preclinical intervention trial of the demethylating agent Decitabine in genetically engineered mice with pancreatic cancer.

1R21CA188857-01 **Olive** **(PI)** 07/01/2014 – 06/31/2016 0.6 months

NIH/NCI				\$261,000 total direct
"Preclinical analysis of a targeted Bmi1 inhibitor in pancreatic cancer"				
The goal of this proposal is to investigate the pharmacology and preclinical efficacy of a novel Bmi1 inhibitor, PTC-596 using genetically engineered models of pancreatic ductal adenocarcinoma.				
1R21CA177591-01A1	Stockwell	(Co-Inv.)	04/01/2014 – 03/31/2016	0.5 months
NIH/NCI				\$12,480 total direct
"Discovery of allele-selective KRAS inhibitors"				
The goal is to create allele-selective inhibitors of activated KRAS.				
Sponsored Research Project	Olive	(PI)	11/01/2014 – 10/31/2015	0.48 months
PTC Therapeutics				\$100,240 total direct
"Gene expression analysis of the effects of PTC-596 on pancreatic tumors"				
RNA-SEQ will be performed on pre- vs. post-treatment pancreatic tumors tumor samples from genetically engineered mice using PTC-596, a targeted Bmi1 inhibitor.				
Sponsored Research Project	Olive	(PI)	11/01/2014 – 10/31/2015	0.48 months
PTC Therapeutics				\$13,750 total direct
"Pilot evaluation of PTC-BDM, a targeted Bmi1 inhibitor"				
Supported early pilot studies of a targeted Bmi1 inhibitor.				
Sponsored Research Project	Olive	(PI)	11/01/2014 – 10/31/2015	0.48 months
Infinity Pharmaceuticals				\$80,769 total direct
"Pilot analysis of the preclinical effects of IPI-9119, a fatty acid synthase inhibitor, on a genetically engineered mouse model of pancreatic cancer."				
This study will explore effects of FASN inhibition on pancreatic ductal adenocarcinoma using the KPC mouse model.				
Cancer Research Fellowship	Olive	(PI)	07/01/2013 – 06/30/2015	0.6 months
Stewart Trust				\$150,000 total direct
"Preclinical evaluation of Bmi1 inhibitor in Pancreatic Ductal Adenocarcinoma"				
Evaluation of PTC-BDM, a Bmi1 inhibitor, in genetically engineered mouse models of pancreatic cancer.				
Bernard L. Schwartz Designated	Olive	(PI)	07/01/2010 – 06/31/2013	2.4 months
Research Scholar Award in Pancreatic Cancer				\$225,000 total direct
American Gastroenterological Association				
"The Influence of Hedgehog Pathway Inhibition on Pancreatic Cancer Metastasis"				
To investigate the mechanisms by which hedgehog pathway inhibitors influence pancreatic cancer metastasis.				
Translational Innovator Award	Olive	(PI)	07/01/2011 – 06/31/2012	0.6 months
Lustgarten Foundation for Pancreatic Cancer Research				\$90,909 total direct
"Preclinical Evaluation of the Mutant-Ras Synthetic Lethal Drug MEII"				
The goal of this proposal is to perform a preclinical trial of MEII, a mutant-Ras synthetic lethal compound, using the KPC model of pancreatic cancer.				
197712	Olive	(PI)	07/01/2011 – 06/31/2013	1.2 months
AACR/PanCan Career Development Award				\$200,000 total direct
"The Role of HIF1 α and Hypoxia in Pancreatic Ductal Adenocarcinoma"				

The goal of this project is to evaluate the effects of hypoxia on pancreatic tumor development and progression, and the role of HIF1a in this process.

1 S10 RR025482-01A2S10 Olive (PI) 06/01/2011 – 05/31/2012 0.0 months
NIH S10 Equipment Grant \$393,698 total direct

“Micro Ultrasound Scanner to Track Tumor Models”

Equipment grant for the purchase of a Vevo 2100 high resolution ultrasound instrument for the HICCC Small Animal Imaging Shared Resource.

Cooperative Research Agreement Olive (PI) 01/01/2011 – 12/31/2011 0.0 months
Infinity Pharmaceuticals Inc. \$41,667 total direct

“Preclinical Evaluation of Combination IPI-926 + Doxorubicin in Pancreatic Ductal Adenocarcinoma”

The goal of this project is to evaluate the preclinical efficacy of the combination of IPI-926 with Doxorubicin in the KPC model of pancreatic ductal adenocarcinoma.

2010 Inter-Programmatic Pilot Olive (PI) 09/01/2010 – 08/31/2011 0.0 months
Herbert Irving Comprehensive Cancer Center \$60,000 total direct

“Preclinical Studies of PARP Inhibition in Pancreatic Cancer”

The aim of this project is to provide pilot data on the efficacy of a Parp inhibitor in mouse models of BRCA-deficient pancreatic cancer.

1F32CA123939 Kirschstein NRSA Olive (PI) 09/25/2006 – 09/24/2009 12 months
NIH/NCI \$124,380 total direct

“Pre-clinical Evaluation of Novel Therapeutics for PDA”

During this postdoctoral fellowship, I developed the Mouse Hospital platform for preclinical evaluation of novel therapeutics in pancreatic ductal adenocarcinoma.

Teaching Experience

Courses and lectures

2022	Lecturer, Columbia University PATH G4500 - “Cellular & Molecular Biology of Cancer”
2022	Lecturer, Columbia University BIOL UN1908 – “First Year Seminar”
2022	Lecturer, Cold Spring Harbor Course, “Foundations in Pancreatic Cancer Research”
2021	Lecturer, Columbia University BIOL UN1908 – “First Year Seminar”
2020	Virtual Lecturer, Cold Spring Harbor Course, “Foundations in Pancreatic Cancer Research”
2019	Lecturer, Columbia University BIOL UN1908 – “First Year Seminar”
2019	Lecturer, Columbia University PATH G4500 - “Cellular & Molecular Biology of Cancer”
2019	Lecturer, Columbia University PHARM G8001 - “Principles of Systems Pharmacology”
2019	Lecturer, Cold Spring Harbor Course, “Foundations in Pancreatic Cancer Research”
2018	Discussion leader, CMBS Responsible Conduct of Research course, session on “Animal and Human research”
2017	Lecturer, Cold Spring Harbor Course, “Foundations in Pancreatic Cancer Research”
	Lecturer, Columbia University PATH G4500 - “Cellular & Molecular Biology of Cancer”
2016	Lecturer, Columbia University PATH G4500 - “Cellular & Molecular Biology of Cancer”
	Discussion leader, Columbia University CMBS Responsible Conduct of Research course, session on “Animal and Human research”
2015	Lecturer, Columbia University PATH G4500 - “Cellular & Molecular Biology of Cancer”
	Discussion leader, Columbia University CMBS Responsible Conduct of Research course, session on “Animal and Human research”
2014	Lecturer, Columbia University PATH G4500 - “Cellular & Molecular Biology of Cancer”

	Discussion leader, Columbia University CMBS Responsible Conduct of Research course, session on “Animal and Human research”
2013	Lecturer, Cold Spring Harbor Laboratories course, "Foundations of Pancreatic Cancer"
	Lecturer, Columbia University PATH G4500 - “Cellular & Molecular Biology of Cancer”
2012	Lecturer, 5th NKI-Curie Course on Preclinical Assays, Amsterdam, Netherlands
	Lecturer, Columbia University PATH G4500 - “Cellular & Molecular Biology of Cancer”
2011	Course Procter and Lecturer, Cold Spring Harbor Laboratories course, “Foundations of Pancreatic Cancer”

Graduate Program Affiliations

2012 – present	Pharmacology and Molecular Signaling Program
2010 – present	Pathobiology and Molecular Medicine
2010 – present	Integrated Program in Cellular, Molecular, and Biomedical Studies

Qualifying exam committees *served as committee Chair

Aditi Trehan*	2022	Integrated Program	Advisor: Xuebing Wu
Bobby Shih*	2020	Integrated Program	Advisors: Teresa Palomero Adolfo Ferrando
Justin Hickman	2018	Pathobiology and Mol. Med.	Advisor: Wei Gu
Alfred von Krusenstiern	2018	MD/Ph.D.	Advisor: Brent Stockwell
Lukas Vlahos	2018	CMBS Program	Advisor: Andrea Califano
Alan Burke	2018	Pharmacology Program	Advisor: Siddhartha Mukherjee
Sunny Jones	2018	CMBS Program	Advisor: Andrea Califano
Alfred Krusenstiern	2018	Integrated Program	Advisor: Brent Stockwell
Justin Hickman	2014	Pathobiology and Mol. Med.	Advisor: Wei Gu
Ian Tattersall	2011	MD/Ph.D.	Advisor: Jan Kitajewski
Sarah Tisdale	2010	Integrated Program	Advisor: Livio Pellizzoni

Thesis committees *served as committee Chair

Alina Li	2022 – present	MD/PhD	Advisor: Anil Rustgi
Eduard Reznik	2021 – present	Biology	Advisor: Brent Stockwell
Alan Burke*	2020 – 2022	Pharmacology	Advisor: Siddhartha Mukherjee
Lukas Vlahos*	2019 – 2022	Systems Biology	Advisor: Andrea Califano
Jared Daniels	2019	Pharmacology	Advisor: Brent Stockwell
Ling Ye	2019	Chemistry	Advisor: Brent Stockwell
Daniela Torres	2018	Pharmacology	Advisor: Peter Canoll
Bill Raab	2017 – 2022	Pathobiology and Mol. Med.	Advisor: Piero Dalerba
Jing He	2016 – 2017	Systems Biology	Advisor: Andrea Califano
Jesse Handler	2016	NYU- MD/PhD Program	Advisor: Dafna Bar-Sagi
Miki Hayano	2015	Pharmacology Program	Advisor: Brent Stockwell
Visanthi Viswanathan	2014	Biology	Advisor: Brent Stockwell
Irina Jilishitz	2013 – 2015	Integrated Program	Advisor: Jan Kitajewski
Gary Hou	2012 – 2013	Biomedical Engineering	Advisor: Elisa Konofagou
Ian Tattersall	2012 – 2014	MD/PhD	Advisor: Jan Kitajewski
Benjamin Hopkins	2012 – 2013	Pathobiology and Mol. Med.	Advisor: Ramon Parsons
Reka Letso	2011	Pathobiology and Mol. Med.	Advisor: Brent Stockwell
Rohitha SriRamaratnam	2011	Chemistry	Advisor: Brent Stockwell
Colin Palmer	2010	Integrated Program	Advisor: Boris Reizis

Clinical fellow committees

Sarah Tannenbaum	2013 – 2015	Pediatric Oncology	Advisor: Darryl Yamashiro
Charlotte Alme	2011 – 2012	Hematology/Oncology	Advisor: Igor Matushansky

Trainees (* indicates current trainees)*Faculty (provided direct research support/laboratory)*

Tamas Gonda	2018 – 2020	Dept. of Medicine, Div. of Digestive and Liver Diseases
-------------	-------------	---

Publication in Cancer Research
Current: Chief of Endoscopy, Associate Professor of Medicine, NYU Langone Medical Center

Gulam Manji	2013 – 2015	Dept. of Medicine, Div. of Hematology and Oncology
-------------	-------------	--

Received ASCO Young Investigator Award.
Current: Assistant Professor of Medicine, Columbia University Medical Center.
Secured R01 grant from NIH and multiple clinical trials.

Paul Oberstein	2011 – 2013	Dept. of Medicine, Div. of Hematology and Oncology
----------------	-------------	--

Received ASCO Young Investigator Award and KL2 grant.
Current: Chief of GI Medical Oncology, NYU Langone Medical Center

Clinical Fellows

*Basil Bakir	2023 – Present	Dept. of Medicine, Div. of Hematology and Oncology
*Mariam El-Ashmawy	2023 – Present	Dept. of Medicine, Div. of Hematology and Oncology

Gulam Manji	2013 – 2015	Dept. of Medicine, Div. of Hematology and Oncology
-------------	-------------	--

Received ASCO Young Investigator Award
Current: Assistant Professor of Medicine and Chief of Pancreas Oncology, CUIMC; has secured NIH R01 grant and multiple clinical trials

Domenico Viterbo	2013 – 2014	Dept. of Medicine, Div. of Digestive & Liver Diseases
------------------	-------------	---

Current: Gastroenterologist, Digestive Disease Center of the Hudson Valley

Paul Oberstein	2011 – 2013	Dept. of Medicine, Div. of Hematology and Oncology
----------------	-------------	--

Received ASCO Young Investigator Award and KL2 grant.
Current: Chief of GI Medical Oncology, NYU Langone Medical Center

Adjunct Associate Research Scientist/Surgical Resident

Kazuki Sugahara	2013 – 2017	Dept. of Surgery, PGY5
-----------------	-------------	------------------------

Postdoctoral Fellows

Marie Hasselluhn*	2020 – Present	Ph.D., Georg-August University School of Science
Alvaro Curiel-Garcia*	2019 – Present	Ph.D., Autónoma University, Madrid, Spain
Michael Badgley	2017 – 2018	Ph.D., Columbia University

Current: Research Associate Scientist, Columbia University Irving Medical Center, Olive Laboratory

Luis Arnes	2016 – 2018	Ph.D., Autónoma University, Madrid, Spain
------------	-------------	---

Current: Associate Professor, University of Copenhagen, Denmark

Hans Carlo Maurer	2015 – 2018	M.D., University of Munich, Germany
-------------------	-------------	-------------------------------------

Current: Clinical Fellow, Technical University of Munich, Germany

Dafydd Thomas	2010 – 2015	Ph.D., 2010; Temple University, Philadelphia, PA
---------------	-------------	--

Current: Principle Scientist, PMV Pharma, Cranberry, NJ

Barbara Orelli 2010 – 2016 Ph.D., 2010; Stony Brook University, Stony Brook, NY
Current: Donor Relations Manager, ETH Zurich Foundation, Zurich, Switzerland

Sam Holmstrom 2012 – 2015 Ph.D., 2005; U. Michigan, Ann Arbor, MI
Current: Consultant, Choice Agility LLC

Jennifer Jongen 2011 – 2012 University of Utrecht, Utrecht, The Netherlands
Current: Surgeon, University of Utrecht, The Netherlands

Doctoral Students

Filko Prugo* 2022 – Present Dept. of Pathology and Cell Biology, CMBS

Tanner Dalton* 2021 – Present Integrated Program, CMBS

Daniel Ross* 2020 – Present Dept. of Pharmacology

Urszula Wasko* 2019 – Present Dept. of Pharmacology

Amanda Decker* 2018 – Present Integrated Program, CMBS

Jaime Eberle-Singh 2013 – 2018 Dept. of Pathology & Cell Biology

Current: 4th year medical student, Thomas Jefferson University, Sidney Kimmel Medical College

Roshan Ahmed 2012 – 2018 Dept. of Pharmacology

Current: Senior Editor, Genome Medicine

Michael Badgley 2011 – 2017 Dept. of Pathology & Cell Biology

Current: Research Associate Scientist, Columbia University Irving Medical Center, Olive Laboratory

Master's Students

Wendy Liu* 2022 – Present Biotechnology

Isabel Goncalves* 2021 – Present Biotechnology

Alice Ma 2018 – Spring, 2020 Biomedical Engineering

Current: Consultant, Clearview Health Partners

Brandon Pecchia 2015 – 2016 Nutrition Program

Current: Medical student, New York Medical College

Undergraduate Students

Sara Chough Fall 2022 – present Columbia University

Harry Xiao* Spring 2022 – present Columbia University

Rose Hollingsworth* Fall 2021 – present Columbia University

Jonathan Kapilian Spring, 2018 – Spring, 2020 Columbia University

Brandon Cuevas Summer, 2017 – Spring, 2020 Columbia University

Christina Firl Summer, 2015 – Spring, 2017 Columbia University

Peter Kim Fall, 2012 – Spring, 2016 Columbia University

Haoxuan Yuan Summer, 2014 – Spring, 2017 Columbia University

Peri Shapiro Fall, 2012 – Spring, 2013 Columbia University

Xidi Ma Fall, 2012 – Spring, 2013 Columbia University

Medical Students

Tessa LeLonge 2016 – 2017 VU Uni. Medical Center, Amsterdam, The Netherlands

Current: Ph.D. Student, VU Medical Center, Amsterdam, The Netherlands

Rotation Graduate Students

Tanner Dalton Spring, 2021 Integrated Program, CMBS

Tarik Zahr	Fall, 2020	Pharmacology and Molecular Signaling
Lindsay Caprio	Summer, 2020	MD/PhD Program
Connor Monahan	Spring, 2020	Integrated Program, CMBS
Fangda Li	Fall, 2019	Integrated Program, CMBS
Alina Li	Summer, 2019	MD/PhD Program
Adam Kornberg	Spring, 2019	Immunology and Microbiology Program
Bobby Shih	Fall, 2018	Integrated Program, CMBS
Timothy Zhong	Fall, 2017	Pathobiology and Molecular Medicine Program
Alyssa Klein	Summer, 2015	MD/PhD Program
Jennifer Frevert	Fall, 2014	Pharmacology Program
William Raab	Fall, 2014	Pathobiology and Molecular Medicine Program
Tiara Ahmad	Spring, 2014	Pathobiology and Molecular Medicine Program
Chelsea Dieck	Spring, 2014	Integrated Program, CMBS
Claudia Becerra	Fall, 2013	Pathobiology and Molecular Medicine Program
Linda Williams	Spring, 2013	Pathobiology and Molecular Medicine Program
Shannon Yoo	Summer, 2012	Pharmacology Program
Jennifer Crowe	Fall, 2011	Pathobiology and Molecular Medicine Program
Angela Xie	Fall, 2011	Pathobiology and Molecular Medicine Program
Sarah Tisdale	Spring, 2010	Integrated Program, CMBS

Post-baccalaureate Students

Karina Hung	Fall, 2012 – Spring 2013	CUMC Post-baccalaureate program
-------------	--------------------------	---------------------------------

Interns

Kadeja Moses	Summer, 2017	Lafayette College
Laura Polanco	Summer, 2016	Lafayette College
Matthew Federbush	Summer, 2015	University of Chicago
Tiffany Phuong	Summer, 2015	Lafayette College
Sahityasri Thapi	Summer, 2015	Columbia University
Farrah Liu	Summer, 2015	The College of New Jersey
Francine Palermo	Summer 2015	Hofstra University
Michael Sigorous	Summer, 2014	Tufts University
Wendi Liu	Summer, 2014	B.A. SUNY Stony Brook
Michael Chen	Summer, 2014	B.S. SUNY Stony Brook
Devorah Leventhal	Spring, 2014	Brooklyn College
David Wu	Fall, 2013	B.S. SUNY Stony Brook
Kaitlyn Bosch	Summer, 2013	B.S. Bucknell University
Ian Chabot	Summer, 2013	High School student
Matthew Levin	Summer, 2012	Northwestern University
Mayté Hernandez-Burgos	Summer, 2011	University of Puerto Rico

Publications

Peer reviewed research articles (*corresponding or first author) – Total of 66

Primary Contributions:

1. *Badgley MA, Kremer DM, Maurer HC, DelGiorno KE, Lee HJ, Purohit V, Sagalovskiy IR, Ma A, Kapilian J, Firl CEM, Decker AR, Sastra SA, Palermo CF, Andrade LR, Sajjakulnukit P, Zhang L, Tolstyka ZP, Hirschhorn T, Lamb C, Liu T, Gu W, Seeley ES, Stone E, Georgiou G, Manor U, Iuga A, Wahl GM, Stockwell BR, Lyssiotis CA, Olive KP. Cysteine depletion induces pancreatic tumor ferroptosis in mice. **Science**. 2020 Apr

- 3;368(6486):85-89. doi: 10.1126/science.aaw9872. PMID: 32241947; PMCID: PMC7681911. Role: PI of entire project; writing; editing; figure designs. **Citations: 353**
2. Payen T, Oberstein PE, Sharkhiz N, Palermo CF, Sastra SA, Han Y, Nabavizadeh A, Sagalovskiy I, Orelli B, Rosario VI, Desrouilleres D, Remotti HE, Kluger MD, Schrope BA, Chabot JA, Iuga A, Konogafou EE,* Olive KP.* “Harmonic Motion Imaging of pancreatic tumor stiffness indicates disease state and treatment”, **Clinical Cancer Research**, DOI: 10.1158/1078-0432.CCR-18-3669 December 2019. Role: Led experimental components; PI of clinical protocol; contributed to conceptualization; writing; editing; figure design. **Citations: 15**
 3. *Eberle-Singh JA, Sagalovskiy I, Maurer HC, Sastra SA, Palermo CF, Decker AR, Kim MJ, Sheedy J, Mollin A, Cao L, Hu J, Branstrom A, Weetall M, Olive KP. Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma. **Clin Cancer Res**. 2019 Sep 15;25(18):5548-5560. doi: 10.1158/1078-0432.CCR-18-3281. Epub 2019 Jun 7. PMID: 31175095. Role: PI of entire project; writing; editing; figure designs. **Citations: 20**
 - 4.*Maurer HC, Holmstrom SR, He J, Su T, Ahmed A, Hibshoosh H, Chabot JA, Oberstein PE, Sepulveda AR, Genkinger JM, Zhang J, Iuga AC, Bansal M, Califano A,* and Olive KP.* “Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes”; **Gut**, Jan 2019 Advance online. Role: Led experimental components and some computational components; intellectual contributions; figure design; writing; editing. **Citations: 103**
 - 5.*Maurer, HC and Olive, KP. “Laser Capture Microdissection on frozen sections for extraction of high-quality nucleic acids”, **Methods Mol Bio**, 1882:253-259, 2019. Role: Project PI; editing. **Citations: 10**
 - 6.*Arnes L, Liu Z, Wang J, Carlo Maurer H, Sagalovskiy I, Sanchez-Martin M, Bommakanti N, Garofalo DC, Balderes DA, Sussel L, Olive KP.* Rabadan R.* “Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma”, **Gut**, Feb 2018, advance online. PMID: 29440233 Role: Co-senior author leading the laboratory components of the research and contributed large-scale RNA-seq dataset; writing and editing. **Citations: 43**
 - 7.*Payen T, Palermo CF, Sastra SA, Chen H, Han Y, Olive KP.* Konofagou EE.* “Elasticity mapping of murine abdominal organs *in vivo* using harmonic motion imaging (HMI).” **Phys Med Biol**, 61(15): 5741-54, 2016. PMID: 27401609. Role: Oversaw *in vivo* studies and analysis of tissues; writing and editing. **Citations: 21**
 8. *Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, Fernandez-Barrena MG, Fernandez-Zapico ME, Iacobuzio-Donahue C, Olive KP*, Stanger BZ*. “Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma”, **Cancer Cell**, 25(6): 735 – 747, 2014. Role: Led all pharmacological experiments (Figs. 3-6, S2-S5); intellectual guidance; data analysis; figure preparation; writing; editing. **Citations: 1609**. NOTE: this article was re-published in a compilation issue of the **top articles in Cancer Cell for 2014**.
 9. *Sastra S. and Olive KP. "Acquisition of tumor biopsies through abdominal laparotomy", **Cold Spring Harb Protoc** Cold Spring Harb Protoc. 2014(1):47-56 2014. PMID: 24371318 PMCID: PMC4084730. Role: Developed method; wrote manuscript; prepared figures. **Citations: 6**
 10. *Sastra SA, Olive KP, "Quantification of murine pancreatic tumors by high-resolution ultrasound." **Methods Mol Biol**. 980: 249-66, 2013. Role: Developed method; wrote manuscript; prepared figures. **Citations: 41**
 11. *Olive KP, Davidson CJ, Jacobetz MA, Honess D, McIntyre D, Madhu B, Goldgraben MA, Frese K, Caldwell ME, DeNicola G, Feig C, Gopinathan A, Combs C, Winter SP, Ireland H, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Iacobuzio-Donahue C, Plunkett W, Egorin M, Hruban RH, McGovern K, Griffiths J, Tuveson DA. “Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer.” **Science**, 324: 1457-1461, 2009. Role: Led entire project; performed all *in vivo* experiments; wrote manuscript; drafted figures. **Citations: 3158**.

12. *Jackson EL* & Olive KP*, Tuveson DA, Bronson R, Crowley D, Brown M, Jacks T. “The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung Cancer.” **Cancer Research**, 65(22): 10280-10288, 2005. Role: Co-led all experiments; co-developed all concepts; co-wrote text and drafted figures. **Citations: 537**
13. *Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. “Mutant p53 Gain-of-Function in Two Mouse Models of Li-Fraumeni Syndrome.” **Cell**, Vol. 119, 847–860, 2004. Role: Led and performed all experiments; developed concepts; wrote manuscript; drafted figures. **Citations: 1339**

Collaborative Contributions:

1. Scales MK, Velez-Delgado A, Steele NG, Schrader HE, Stabnick AM, Yan W, Mercado Soto NM, Nwosu ZC, Johnson C, Zhang Y, Salas-Escabillas DJ, Menjivar RE, Maurer HC, Crawford HC, Bednar F, Olive KP, Pasca di Magliano M, Allen BL. Combinatorial Gli activity directs immune infiltration and tumor growth in pancreatic cancer. *PLoS Genet*. 2022 Jul 22;18(7):e1010315. doi: 10.1371/journal.pgen.1010315. PMID: 35867772; PMCID: PMC9348714.
2. Patel KB, Liang W, Casper MJ, Voleti V, Li W, Yagielski AJ, Zhao HT, Perez Campos C, Lee GS, Liu JM, Philipone E, Yoon AJ, Olive KP, Coley SM, Hillman EMC. High-speed light-sheet microscopy for the in-situ acquisition of volumetric histological images of living tissue. **Nat Biomed Eng**. 2022 May;6(5):569-583. doi: 10.1038/s41551-022-00849-7. Epub 2022 Mar 28. PMID: 35347275.
3. Caplan LR, Vavinskaya V, Gelikman DG, Jyotsana N, Trinh VQ, Olive KP, Tan MCB, DelGiorno KE. Enteroendocrine Cell Formation Is an Early Event in Pancreatic Tumorigenesis. **Front Physiol**. 2022 Apr 27;13:865452. doi: 10.3389/fphys.2022.865452. PMID: 35574446; PMCID: PMC9091171.
4. Nakkina SP, Gitto SB, Pandey V, Parikh JG, Geerts D, Maurer HC, Olive KP, Phanstiel O 4th, Altomare DA. Differential Expression of Polyamine Pathways in Human Pancreatic Tumor Progression and Effects of Polyamine Blockade on Tumor Microenvironment. **Cancers (Basel)**. 2021 Dec 20;13(24):6391. doi: 10.3390/cancers13246391. PMID: 34945011; PMCID: PMC8699198. Citations: 4
5. Kremer DM, Nelson BS, Lin L, Yarosz EL, Halbrook CJ, Kerk SA, Sajjakulnukit P, Myers A, Thurston G, Hou SW, Carpenter ES, Andren AC, Nwosu ZC, Cusmano N, Wisner S, Mbah NE, Shan M, Das NK, Magnuson B, Little AC, Savani MR, Ramos J, Gao T, Sastra SA, Palermo CF, Badgley MA, Zhang L, Asara JM, McBrayer SK, di Magliano MP, Crawford HC, Shah YM, Olive KP, Lyssiotis CA. GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis. **Nat Commun**. 2021 Aug 11;12(1):4860. doi: 10.1038/s41467-021-24859-2. PMID: 34381026; PMCID: PMC8357841. Citations: 35
6. Singhal R, Mitta SR, Das NK, Kerk SA, Sajjakulnukit P, Solanki S, Andren A, Kumar R, Olive KP, Banerjee R, Lyssiotis CA, Shah YM. HIF-2 α activation potentiates oxidative cell death in colorectal cancers by increasing cellular iron. **J Clin Invest**. 2021 Jun 15;131(12). doi: 10.1172/JCI143691. PubMed PMID: 33914705; PubMed Central PMCID: PMC8203462. Citations: 27
7. Bhattacharjee S, Hamberger F, Ravichandra A, Miller M, Nair A, Affo S, Filliol A, Chin L, Savage TM, Yin D, Wirsik NM, Mehal A, Arpaia N, Seki E, Mack M, Zhu D, Sims PA, Kalluri R, Stanger BZ, Olive KP, Schmidt T, Wells RG, Mederacke I, Schwabe RF. Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. **J Clin Invest**. 2021 Jun 1;131(11). doi: 10.1172/JCI146987. PubMed PMID: 33905375; PubMed Central PMCID: PMC8159701. Citations: 52
8. Thomas D, Sagar S, Liu X, Lee HR, Grunkemeyer JA, Grandgenett PM, Caffrey T, O'Connell KA, Swanson B, Marcos-Silva L, Steentoft C, Wandall HH, Maurer HC, Peng XL, Yeh JJ, Qiu F, Yu F, Madiyalakan R, Olive KP, Mandel U, Clausen H, Hollingsworth MA, Radhakrishnan P. Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer. **Mol Ther**. 2021 Apr 7;29(4):1557-1571. doi: 10.1016/j.ymthe.2020.12.029. Epub 2020 Dec 25. PubMed PMID: 33359791; PubMed Central PMCID: PMC8058431. Citations: 13

9. Poelaert BJ, Knoche SM, Larson AC, Pandey P, Seshacharyulu P, Khan N, Maurer HC, Olive KP, Sheinin Y, Ahmad R, Singh AB, Batra SK, Rachagani S, Solheim JC. Amyloid Precursor-like Protein 2 Expression Increases during Pancreatic Cancer Development and Shortens the Survival of a Spontaneous Mouse Model of Pancreatic Cancer. **Cancers (Basel)**. 2021 Mar 26;13(7). doi: 10.3390/cancers13071535. PubMed PMID: 33810510; PubMed Central PMCID: PMC8036577.
10. Liotta L, Lange S, Maurer HC, Olive KP, Braren R, Pfarr N, Burger S, Muckenhuber A, Jesinghaus M, Steiger K, Weichert W, Friess H, Schmid R, Algül H, Jost PJ, Ramser J, Fischer C, Quante AS, Reichert M, Quante M. PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer. **JCI Insight**. 2021 Mar 25;6(8). doi: 10.1172/jci.insight.141532. PubMed PMID: 33764904; PubMed Central PMCID: PMC8119201. Citations: 2
11. Takahashi R, Macchini M, Sunagawa M, Jiang Z, Tanaka T, Valenti G, Renz BW, White RA, Hayakawa Y, Westphalen CB, Tailor Y, Iuga AC, Gonda TA, Genkinger J, Olive KP, Wang TC. Interleukin-1 β -induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression. **Gut**. 2021 Feb;70(2):330-341. doi: 10.1136/gutjnl-2019-319912. Epub 2020 May 10. PubMed PMID: 32393543. Citations: 32
12. Kahn BM, Lucas A, Alur RG, Wengyn MD, Schwartz GW, Li J, Sun K, Maurer HC, Olive KP, Faryabi RB, Stanger BZ. The vascular landscape of human cancer. **J Clin Invest**. 2021 Jan 19;131(2). doi: 10.1172/JCI136655. PubMed PMID: 33258803; PubMed Central PMCID: PMC7810485. Citations: 12
13. Cannon A, Thompson CM, Maurer HC, Atri P, Bhatia R, West S, Ghersi D, Olive KP, Kumar S, Batra SK. CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma. **Clin Cancer Res**. 2020 Nov 15;26(22):6051-6063. doi: 10.1158/1078-0432.CCR-20-1359. Epub 2020 Sep 1. PubMed PMID: 32873571; PubMed Central PMCID: PMC8261859. Citations: 8
14. Gonda TA, Fang J, Salas M, Do C, Hsu E, Zhukovskaya A, Siegel A, Takahashi R, Lopez-Bujanda ZA, Drake CG, Manji GA, Wang TC, Olive KP, Tycko B. A DNA Hypomethylating Drug Alters the Tumor Microenvironment and Improves the Effectiveness of Immune Checkpoint Inhibitors in a Mouse Model of Pancreatic Cancer. **Cancer Res**. 2020 Nov 1;80(21):4754-4767. doi: 10.1158/0008-5472.CAN-20-0285. Epub 2020 Aug 14. PubMed PMID: 32816859. Citations: 23
15. DelGiorno KE, Chung CY, Vavinskaya V, Maurer HC, Novak SW, Lytle NK, Ma Z, Giraddi RR, Wang D, Fang L, Naeem RF, Andrade LR, Ali WH, Tseng H, Tsui C, Gubbala VB, Ridinger-Saison M, Ohmoto M, Erikson GA, O'Connor C, Shokhirev MN, Hah N, Urade Y, Matsumoto I, Kaech SM, Singh PK, Manor U, Olive KP, Wahl GM. Tuft Cells Inhibit Pancreatic Tumorigenesis in Mice by Producing Prostaglandin D2. **Gastroenterology**. 2020 Nov;159(5):1866-1881.e8. doi: 10.1053/j.gastro.2020.07.037. Epub 2020 Jul 24. PubMed PMID: 32717220; PubMed Central PMCID: PMC7680354. Citations: 21
16. Sliker BH, Goetz BT, Barnes R, King H, Maurer HC, Olive KP, Solheim JC. HLA-B influences integrin beta-1 expression and pancreatic cancer cell migration. **Exp Cell Res**. 2020 May 15;390(2):111960. doi: 10.1016/j.yexcr.2020.111960. Epub 2020 Mar 16. PubMed PMID: 32194036; PubMed Central PMCID: PMC7182497. Citations: 5
17. Nabavizadeh A, Payen T, Iuga AC, Sagalovskiy IR, Desrouilleres D, Saharkhiz N, Palermo CF, Sastra SA, Oberstein PE, Rosario V, Kluger MD, Schrope BA, Chabot JA, Olive KP, Konofagou EE. Noninvasive Young's modulus visualization of fibrosis progression and delineation of pancreatic ductal adenocarcinoma (PDAC) tumors using Harmonic Motion Elastography (HME) *in vivo*. **Theranostics**. 2020 Mar 15;10(10):4614-4626. doi: 10.7150/thno.37965. PMID: 32292518; PMCID: PMC7150482. Citations: 17
18. Venkat S, Tisdale AA, Schwarz JR, Alahmari AA, Maurer HC, Olive KP, Eng KH, Feigin ME. Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma. **Genome Res**. 2020 Mar;30(3):347-360. doi: 10.1101/gr.257550.119. Epub 2020 Feb 6. PubMed PMID: 32029502; PubMed Central PMCID: PMC7111527. Citations: 28

19. Michaelis KA, Norgard MA, Zhu X, Levasseur PR, Sivagnanam S, Liudahl SM, Burfeind KG, Olson B, Pelz KR, Ramos DMA, Maurer HC, Olive KP, Coussens LM, Morgan TK, Marks DL. Publisher Correction: The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. **Nat Commun.** 2019 Nov 15;10(1):5257. doi: 10.1038/s41467-019-13151-z. PubMed PMID: 31729370; PubMed Central PMCID: PMC6858433. Citations: 80
20. Lowe ME, Andersen DK, Caprioli RM, Choudhary J, Cruz-Monserrate Z, Dasyam AK, Forsmark CE, Gorelick FS, Gray JW, Haupt M, Kelly KA, Olive KP, Plevritis SK, Rappaport N, Roth HR, Steen H, Swamidass SJ, Tirkes T, Uc A, Veselkov K, Whitcomb DC, Habtezion A. Precision Medicine in Pancreatic Disease-Knowledge Gaps and Research Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. **Pancreas.** 2019 Nov/Dec;48(10):1250-1258. doi: 10.1097/MPA.0000000000001412. PubMed PMID: 31688587; PubMed Central PMCID: PMC7282491. Citations: 10
21. Jain A, Agostini LC, McCarthy GA, Chand SN, Ramirez A, Nevler A, Cozzitorto J, Schultz CW, Lowder CY, Smith KM, Waddell ID, Raitses-Gurevich M, Stossel C, Gorman YG, Atias D, Yeo CJ, Winter JM, Olive KP, Golan T, Pishvaian MJ, Ogilvie D, James DI, Jordan AM, Brody JR. Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. **Cancer Res.** 2019 Sep 1;79(17):4491-4502. doi: 10.1158/0008-5472.CAN-18-3645. Epub 2019 Jul 4. PubMed PMID: 31273064; PubMed Central PMCID: PMC6816506. Citations: 23
22. Le Large TYS, El Hassouni B, Funel N, Kok B, Piersma SR, Pham TV, Olive KP, Kazemier G, van Laarhoven HWM, Jimenez CR, Bijlsma MF, Giovannetti E. Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. **Ther Adv Med Oncol.** 2019;11:1758835919841233. doi: 10.1177/1758835919841233. eCollection 2019. PubMed PMID: 31205498; PubMed Central PMCID: PMC6535709. Citations: 23
23. Abdalla MY, Ahmad IM, Rachagani S, Banerjee K, Thompson CM, Maurer HC, Olive KP, Bailey KL, Britigan BE, Kumar S. "Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by heme oxygenase-1 inhibition"; **Transl Res**, Jan 2019. Citations: 30
24. Renz BW, Tanaka T, Sunagawa M, Takahashi R, Jiang Z, Macchini M, Dantes Z, Valenti G, White RA, Middelhoff MA, Ilmer M, Oberstein PE, Angele MK, Deng H, Hayakawa Y, Westphalen CB, Werner J, Remotti H, Reichert M, Tailor YH, Nagar K, Friedman RA, Iuga AC, Olive KP, Wang TC; "Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness", **Cancer Discovery**, 8(11): 1458-1473, 2018. Role: Assisted with mouse models, data interpretation. Citations: 105
25. Nabavizadeh A, Payen T, Saharkhiz N, McGarry M, Olive KP, Konofagou EE; "In vivo Young's modulus mapping of pancreatic ductal adenocarcinoma during HIFU ablation using harmonic motion elastography (HME)", **Med Phys.**, Advanced online, 2018. Role: Intellectual contributions; provision of research animals. Citations: 6
26. Renz BW, Takahashi R, Tanaka T, Macchini M, Hayakawa Y, Dantes Z, Maurer HC, Chen X, Jiang Z, Westphalen CB, Ilmer M, Valenti G, Mohanta SK, Habenicht AJR, Middelhoff M, Chu T, Nagar K, Tailor Y, Casadei R, Di Marco M, Kleespies A, Friedman RA, Remotti H, Reichert M, Worthley DL, Neumann J, Werner J, Iuga AC, Olive KP, Wang TC. "β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer", **Cancer Cell**, 33 (1): 75-90, 2017. PMID: 29249692 Role: Advised on *in vivo* studies and imaging; contributed genetically engineered mice. **Citations: 218**
27. Welsch ME, Kaplan A, Chambers JM, Stokes ME, Bos PH, Zask A, Zhang Y, Sanchez-Martin M, Badgley MA, Huang CS, Tran TH, Akkiraju H, Brown LM, Nandakumar R, Cremers S, Yang WS, Tong L, Olive KP, Ferrando A, Stockwell BR. "Multivalent Small-Molecule Pan-RAS Inhibitors" **Cell**, 168 (5): 878-889, 2017. PMID: 28235199 Role: Oversaw experiment in KP^{F/F}C mouse model. **Citations: 186**
28. Westphalen CB, Takemoto Y, Tanaka T, Macchini M, Jiang Z, Renz BW, Chen X, Ormanns S, Nagar K, Tailor Y, May R, Cho Y, Asfaha S, Worthley DL, Hayakawa Y, Urbanska AM, Quante M, Reichert M, Broyde J, Subramaniam PS, Remotti H, Su GH, Rustgi AK, Friedman RA, Honig B, Califano A, Houchen CW, Olive KP, Wang TC. "Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and

- Tumorigenesis.” **Cell Stem Cell**, 18(4): 441-55, 2016. Role: Advised on *in vivo* studies and imaging, and contributed mice. **Citations: 161**
29. Chen H, Hou GY, Han Y, Payen T, Palermo CF, Olive KP, Konofagou EE. “Harmonic motion imaging for abdominal tumor detection and high-intensity focused ultrasound ablation monitoring: an *in vivo* feasibility study in a transgenic mouse model of pancreatic cancer.” **IEEE Trans Ultrason Ferroelectr Freq Control**, 62(9): 1662-73, 2015. PMID: 2641512. Role: Oversaw *in vivo* experiments; provided histology; editing. **Citations: 23**
 30. Bednar F, Schofield HK, Collins MA, Yan W, Zhang Y, Shyam N, Eberle JA, Almada LL, Olive KP, Bardeesy N, Fernandez-Zapico ME, Nakada D, Simeone DM, Morrison SJ, Pasca di Magliano M. “Bmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanism”, **Carcinogenesis**, 2015 [epub ahead of print] PMID: 25939753. Role: Contributed an immunohistochemistry experiment. Citations: 29
 31. Jain S, Jirau-Serrano X, Zullo KM, Scotto L, Palermo CF, Sastra SA, Olive KP, Cremers S, Thomas T, Wei Y, Zhang Y, Bhagat G, Amengual JE, Deng C, Karan C, Realubit R, Bates SE, O'Connor OA.” Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma.” **Clin Cancer Res**. 2015. PMID: 25677697. Role: Advised on imaging techniques and analysis. Citations: 47
 32. Harmsen S, Huang R, Wall MA, Karabeber H, Samii JM, Spaliviero M, White JR, Monette S, O'Connor R, Pitter KL, Sastra SA, Saborowski M, Holland EC, Singer S, Olive KP, Lowe SW, Blasberg RG, Kircher MF. “Surface-enhanced resonance Raman scattering nanostars for high-precision cancer imaging.” **Sci Transl Med**. 7(271):271ra7, 2015. PMID: 25609167. Role: Contributed genetically engineered models. Citations: 247
 33. DelGiorno KE, Hall JC, Takeuchi KK, Pan FC, Halbrook CJ, Washington MK, Olive KP, Spence J, Sipos B, Wright CVE, Wells JM, Crawford HC. “Identification and manipulation of biliary metaplasia in pancreatic tumors.” 2013. **Gastroenterology**, 146(1):233-44, 2014. PMID: 23999170. Role: Contributed mouse tissue samples. Citations: 93
 34. Shakya R, Gonda TA, Quante M, Salas M, Kim S, Brooks J, Hirsch S, Davies J, Cullo A, Olive KP, Szabolcs M, Wang TC, Tycko B, Ludwig T. “Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma.” **Cancer Research**, 73(2): 885-96, 2012. Role: Intellectual contributions; advice on mouse models. Citations: 70
 35. Bapiro TE, Richards FM, Goldgraben MA, Olive KP, Madhu B, Frese KK, Cook N, Jacobetz MA, Smith DM, Tuveson DA, Griffiths JR, Jodrell DI. “A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.” **Cancer Chemother Pharmacol**, 68(5):1243-53, 2011. Role: Developed NMR method; generated biological samples; intellectual guidance. Citations: 59
 36. Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, Davies SE, Olive KP, Tuveson DA, Venkitaraman AR. “Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer.” **Cancer Cell**, 18(5):499-509, 2010. Role: Analyzed histopathology; intellectual contributions. Citations: 166
 37. Bertout JA* & Patel JA*, Fryer BH, Durham AC, Covello KA, Olive KP, Goldschmidt MH, Simon, MC. “Heterozygosity for Hypoxia Inducible Factor 1 α decreases the incidence of thymic lymphosarcomas in a p53 mutant mouse model.” **Cancer Research**, 69(7): 3213- 3220, 2009. Role: Advised on analysis of mouse models. Citations: 47
 38. Cook N, Olive KP, Frese K, Tuveson DA. “K-ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses.” **Methods in Enzymology**, 439: 73 – 85. Role: Developed concepts; edited manuscript. Citations: 35

39. Wijnhoven SW, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA, Jonkers J, Schaap MM, van den Berg J, Jacks T, van Steeg H, de Vries A. "Mice Expressing a Mammary Gland-Specific R270H Mutation in the p53 Tumor Suppressor Gene Mimic Human Breast Cancer Development." **Cancer Research**, v. 65 (18): 8166 – 8173. Role: Contributed to generation of mice. Citations: 79

Review Articles (*corresponding or first author) 12 total, 8 primary author.

1. *Curiel-Garcia A, Olive KP. "Modeling Pancreatic Cancer through Somatic Editing with AAV." **Cell Press**, 25(5): 361-362, 2019. PMID: 30878400.
2. Manji GA, Olive KP, Saenger YM, Oberstein P. "Current and Emerging Therapies in Metastatic Pancreatic Cancer." **Clin Cancer Res**, 23(7): 1670-1678, 2017. PMID: 28373365. Role: Editing. Citations: 102
3. *Olive KP. "Fanning the Flames of Cancer Chemoresistance: Inflammation and Anticancer Therapy", **J Oncol Pract**, 13(3): 181-183 2017. PMID: 28282273. Citations: 5
4. *Olive KP. "Stroma, Stroma Everywhere (Far More Than You Think)" **Clin Cancer Res**, 21(15):3366-8, 2015. PMID: 25979482. Citations: 19
5. * Holmstrom SR, Olive KP. "Protein breakdown precedes pancreatic tumor development." **Nature Medicine**, 20(10): 1097-9, 2014. PMID: 25295937. Role: Writing and editing; drafted figures. Citations: 6
6. *Olive KP, and Politi K, "Translational Therapeutics in Genetically Engineered Mouse Models of Cancer", **Cold Spring Harb Protoc**, Cold Spring Harb Protoc. 2014(2):131-43, 2014. PMID: 24492770. Role: Writing and editing; drafted figures. Citations: 12
7. *Oberstein PE and Olive KP, "Pancreatic Cancer: Why is it so hard to treat?" **Therapeutic Advances in Gastroenterology**, Advanced Online Publication, March 7, 2013. PMID: 23814611. Role: Writing and editing; drafted figures. Citations: 324
8. Chin L, de Sauvage F, Egeblad M, Olive KP, Tuveson D, Weiss W., "Recapitulating human cancer in a mouse." **Nat Biotechnol**, 31(5):392-5, 2013. PMID: 23657389. Role: Interview subject. Citations: 7
9. *Westphalen CB and Olive KP, "Genetically engineered mouse models of pancreatic cancer." **Cancer J**, 18(6): 502-10, 2012. PMID: 23187836. Writing and editing. Citations: 120
10. *Cox AD and Olive KP. "Silencing the killers: paracrine immune suppression in pancreatic cancer." **Cancer Cell**, 21(6) 715 – 716, 2012. PMID: 22698396. Writing and editing. Citations: 12
11. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, Tuveson DA. "Stromal biology and therapy in pancreatic cancer." **Gut**, 60(6):861-8, 2011. PMID: 20966025. Role: Editing. Citations: 770
12. *Olive KP and Tuveson DA. *The Use of Targeted Mouse Models for Preclinical Testing of Novel Cancer Therapeutics*. **Clin Cancer Res**, 12(18): 5277-5287, 2006. PMID: 17000660. Role: Writing. Citations: 285
13. Kim CF, Jackson EL, Kirsch DG, Grimm J, Shaw AT, Lane K, Kissil J, Olive KP, Sweet-Cordero A, Weissleder R, Jacks T. *Mouse models of human non-small-cell lung cancer: raising the bar*. **Cold Spring Harb Symp Quant Biol**, 2005;70:241-50. PMID: 16869760. Role: Editing. Citations: 71

Books and Chapters

1. Abate-Shen CA, Politi KP, Chodosh L, and Olive KP. "Mouse Models of Cancer", **Cold Spring Harbor Laboratories Press**, 2014. Role: Editor. Citations: 4

Other invited publications

1. Olive, KP. "Ras-dependent paracrine cascades". National Cancer Institute Ras blog, published August 17, 2017. <https://www.cancer.gov/research/key-initiatives/ras/ras-central/blog/2017/paracrine-cascades>

Invited or Peer-selected presentations (total 77)

- 06/2022 Invited Lecture, European Society for Molecular Oncology (virtual), "Pancreatic cancer preclinical models".
- 04/2022 Invited Lecture, University of New Hampshire (virtual), "Translational cancer research on pancreatic ductal adenocarcinoma".
- 03/2022 Invited Lecture, University of Colorado (virtual), "Targeting epithelial and stromal heterogeneity in pancreatic cancer".
- 03/2022 Invited Lecture, New York Genome Center (virtual), "Modeling paracrine cascades in pancreatic ductal adenocarcinoma with tumor explants".
- 12/2021 Invited Lecture, Memorial Sloan Kettering Cancer Center, "A transdisciplinary approach to targeting critical dependencies in pancreatic cancer".
- 11/2021 Invited Lecture, NCI Working Group on Preclinical Models (virtual), "Modeling paracrine cascades in pancreatic ductal adenocarcinoma with tumor explants".
- 09/2021 Invited Debate, AACR Special Conference on Pancreatic Cancer (virtual), "The KPC model has helped advance pancreatic cancer therapy: Agree".
- 08/2021 Invited Lecture, Bristol-Myers Squibb (virtual), "Parsing local immunosuppression in pancreatic cancer".
- 04/2021 Invited Lecture, NCI Pancreatic Cancer Clinical Trials Working Group (virtual), "Cisplatin-sensitivity of Brca2-mutant pancreatic tumors is dependent on mitotic functions".
- 03/2021 Invited Lecture, Drexel University (virtual). "Targeting vulnerabilities in pancreatic cancer metabolism and transcriptional regulatory state".
- 11/2020 Invited Lecture, Sanofi Aventis (virtual). "Targeting vulnerabilities in pancreatic cancer metabolism and transcriptional regulatory state".
- 10/2020 Invited Lecture, PTC Therapeutics (virtual). "Targeting vulnerabilities in pancreatic cancer metabolism and transcriptional regulatory state".
- 08/2020 Invited Lecture, PanCAN/BMS meeting (virtual). "Therapeutic induction of tumor-selective ferroptosis in models of pancreatic cancer".
- 06/2020 Invited Lecture, CSHL Pancreatic Cancer Course, (virtual) "Mouse models of pancreatic cancer".
- 06/2020 Invited Lecture, AACR Metabolism, (virtual). "Therapeutic induction of tumor-selective ferroptosis in models of pancreatic cancer".
- 01/2020 Invited Lecture, Bristol-Myers-Squibb, Princeton, NJ. "Single-cell master regulatory analysis reveals cellular heterogeneity of pancreatic cancer".
- 11/2019 Invited Lecture, Merck, Boston, MA. "Targeting paracrine signaling cascades in pancreatic ductal adenocarcinoma".
- 09/2019 Invited Lecture, Huntsman Cancer Institute, Salt Lake City, UT. "Multidisciplinary studies of pancreatic cancer: systems, metabolism, and translational therapeutics".
- 07/2019 Peer selected lecture, Salk Mechanisms and Models of Cancer Meeting, La Jolla, CA. "Cystine import is a critical dependency of pancreatic cancer"
- 07/2019 Invited Lecture, NIDDK, Pittsburgh, PA, "Transforming Precision Medicine to Personalized Medicine"
- 02/2019 Invited Lecture, Keystone Symposia Conference, Keystone, CO, "Modulation of Cystine Import Induces Pancreatic Cancer-Selective Ferroptosis"
- 02/2019 Invited Lecture, Oregon Health Sciences University, Portland, OR, "Multidisciplinary studies of pancreatic cancer: systems, metabolism, and translational therapeutics"
- 12/2018 Invited Lecture, Thomas Jefferson University, Philadelphia, PA, "Multidisciplinary studies of pancreatic cancer: systems, metabolism, and translational therapeutics"
- 11/2018 Invited Lecture, New York University Langone Medical Center, New York, NY, "Multidisciplinary studies of pancreatic cancer: systems, metabolism, and translational therapeutics"

- 10/2018 Invited Lecture, Mayo Clinic, Rochester, MN "Multidisciplinary studies of pancreatic cancer: systems, metabolism, and translational therapeutics"
- 09/2018 Invited Lecture, AACR Pancreatic Cancer Meeting
- 09/2018 Invited Lecture, ASBMB Meeting on Ras Pathobiology and Cancer, Stratton, VT, "Leveraging the dependency of pancreatic tumor cells on ROS detoxification"
- 05/2018 Invited Lecture, New York Academy of Sciences Meeting on Cancer Metabolism, New York, NY, "Leveraging the dependency of pancreatic tumor cells on ROS detoxification"
- 04/2018 Invited Lecture, Medical College of Wisconsin, Milwaukee, WI, "Multidisciplinary studies of pancreatic cancer: systems, metabolism, and translational therapeutics"
- 03/2018 Invited Lecture, PTC Therapeutics, South Plainfield, NJ, "Preclinical efficacy of PTC-596 in pancreatic cancer"
- 10/2017 Invited Lecture, Roswell Park Comprehensive Cancer Center, Buffalo, NY, "Multidisciplinary studies of pancreatic cancer"
- 10/2017 Invited Lecture, "Understanding paracrine interactions in pancreatic ductal adenocarcinoma", Bristol Myers Squibb symposium on tumor explant models.
- 08/2017 Peer Selected Lecture, Salk Institute Mechanisms and Models of Cancer Meeting "Leveraging the dependency of pancreatic tumor cells on ROS detoxification"
- 05/2017 Invited lecture, University of Pennsylvania Bassler Institute Symposium on BRCA, "Selective sensitivity of Brca2-mutant pancreatic tumors is dependent on mitotic functions"
- 11/2016 Invited lecture, Mayo Clinic symposium on pancreatic cancer, "Selective sensitivity of Brca2-mutant pancreatic cancer is dependent on mitotic functions"
- 05/2016 Invited lecture, Project Purple symposium at University of Nebraska, Omaha, NB. "Compartment-specific regulatory networks in pancreatic cancer"
- 03/2015 Invited lecture, University of Nebraska, Omaha, NB. "Preclinical Therapeutics in Genetically Engineered Models of Pancreatic Cancer"
- 11/2014 Invited lecture, University of Michigan, Ann Arbor, MI. "Preclinical Therapeutics in Genetically Engineered Models of Pancreatic Cancer"
- 04/2014 Peer Selected Lecture, AACR Annual Meeting, San Diego, CA. "The Role(s) of Tumor Stroma in Pancreatic Cancer Chemoresistance"
- 04/2014 Invited Lecture, AACR Annual Meeting, San Diego, CA. Career Development Session. "How to Distinguish Yourself From Your Mentor"
- 03/2014 PTC Therapeutics, South Plainfield, NJ. "Preclinical Therapeutics in Genetically Engineered Models of Pancreatic Cancer"
- 02/2014 Molecular Triconference, San Francisco, CA. "The Role(s) of Tumor Stroma in Pancreatic Cancer Chemoresistance"
- 11/2013 Gilead Pharmaceuticals, Foster City, CA. "Preclinical Therapeutics in Genetically Engineered Models of Pancreatic Cancer"
- 11/2013 AACR Conference, Translational Preclinical Models in Cancer, San Diego, CA
- 11/2013 MMHCC Co-clinical trials meeting, BIDM, Harvard Medical, MA "Sharpening the tools: Technological Innovations for Performing Co-Clinical Trials"
- 08/2013 Salk Institute Mechanisms and Models of Cancer Symposium, La Jolla, CA. "Paradoxical acceleration of pancreatic tumorigenesis by Smoothened inhibition: a post-clinical trial"
- 06/2013 GI Research Academy, Kyoto, Japan. "Paradoxical acceleration of pancreatic tumorigenesis by Smoothened inhibition: a post-clinical trial"
- 04/2013 Bruker, AACR Meeting, "Evaluating Mouse Tumor Models Using Compact MRI"
- 03/2013 Grand Grounds, Winship Cancer Institute, Emory University Cancer Center, Atlanta, GA, "Preclinical Therapeutics in Genetically Engineered Mouse Models of Pancreatic Cancer"
- 02/2013 Preclinical Therapeutics, Banbury Course on Pancreatic Cancer, Banbury, NY. "Translational Therapeutics and genetically engineered models of pancreatic cancer".
- 08/2013 Presentation to NCI Pancreatic Cancer Working Group Teleconference

- 10/2012 Medical College of Wisconsin, Cancer Cell Biology Seminar Series, Milwaukee, WI, "Preclinical Therapeutics in Genetically Engineered Mouse Models of Pancreatic Cancer"
- 09/2012 Netherlands Cancer Institute, "Preclinical Therapeutics in Genetically Engineered Mouse Models of Pancreatic Cancer"
- 06/2012 Stony Brook University, Dept. of Pharmacology, Student Symposium, Stony Brook, NY, "Therapeutic Intervention Targeting a Hedgehog-dependent Barrier to Drug Delivery in Pancreatic Cancer"
- 06/2012 World Pharma Congress, Philadelphia, PA, Therapeutic Intervention Targeting a Hedgehog-dependent Barrier to Drug Delivery in Pancreatic Cancer"
- 06/2012 Tufts University, GI Division, Grand Rounds, Boston, MA, Therapeutic Intervention Targeting a Hedgehog-dependent Barrier to Drug Delivery in Pancreatic Cancer"
- 06/2012 NIH MMHCC Annual Meeting, Washington DC, "Lessons From the Translation of Smoothened Inhibitors in Pancreatic Cancer"
- 06/2012 AACR/PanCAN Pancreatic Cancer Meeting, Lake Tahoe, NV, "Lessons From the Translation of Smoothened Inhibitors in Pancreatic Cancer"
- 05/2012 Digestive Diseases Week, San Diego, CA, "Targeting the Stroma of Pancreatic Cancer"
- 04/2012 Bucknell University, Biochemistry Seminar Series, Lewisburg, PA, "Therapeutic Intervention Targeting Hedgehog-dependent Barrier to Drug Delivery in Pancreatic Cancer"
- 04/2012 AACR Annual Meeting, Chicago, IL, "Meet the expert session: Career Development in Pancreatic Cancer"
- 02/2012 Yale University, GI Division, Grand Rounds, New Haven, CT, Therapeutic Intervention Targeting a Hedgehog-dependent Barrier to Drug Delivery in Pancreatic Cancer"
- 01/2012 ASCO GI Mtg, San Francisco, CA, "Facilitating Drug Delivery in Pancreatic Cancer" and "Therapeutic Intervention Targeting a Hedgehog-dependent Barrier to Drug Delivery in Pancreatic Cancer"
- 11/2011 German Pancreatic Club Annual Meeting, International Invited Speaker, Marburg, Germany, "Facilitating Drug Delivery in Pancreatic Cancer"
- 11/2011 University of Pennsylvania, GI Division, Philadelphia, PA, "Therapeutic Intervention Targeting Hedgehog-dependent Barrier to Drug Delivery in Pancreatic Cancer."
- 11/2011 American Pancreatic Association Annual Meeting, Chicago, IL, "Facilitating Drug Delivery in Pancreatic Cancer"
- 11/2011 Columbia University Board of Visitors Meeting, Metropolitan Club, NYC, "Facilitating Drug Delivery in Pancreatic Cancer"
- 08/2011 University of Colorado, Cancer Imaging Symposium (Keynote Speaker), Boulder, CO, "Using Ultrasound to Monitor Drug Delivery"
- 08/2011 Genentech, South San Francisco, CA, "Therapeutic Intervention Targeting a Hedgehog-dependent Barrier to Drug Delivery in Pancreatic Cancer."
- 06/2011 Cold Spring Harbor Course: Foundations in Pancreatic Cancer, NY, two talks (1) "The Non-Immune Pancreatic Stroma" and (2) "Building the Foundations of a Mouse Hospital"
- 11/2011 MMHCC Co-clinical Trials Meeting, Boston, MA. "Bricks and Mortar: Building the Foundations of a Mouse Hospital"
- 11/2010 AH&MRC Annual Meeting, International Invited Speaker, Melbourne, Australia, "Therapeutic Intervention Targeting a Hedgehog-dependent Barrier to Drug Delivery in Pancreatic Cancer"
- 11/2010 Garvan Institute, Sydney, Australia, "Therapeutic Intervention Targeting a Hedgehog-dependent Barrier to Drug Delivery in Pancreatic Cancer"
- 10/2010 Infinity Pharmaceuticals, Cambridge, MA, "Therapeutic Intervention Targeting a Hedgehog-dependent Barrier to Drug Delivery in Pancreatic Cancer"
- 07/2010 AACR Translational Medicine (USA), San Francisco, "Identification of a Hedgehog Pathway- Dependent Barrier to Drug Delivery Using a Kras/p53-Driven Mouse Model of Pancreatic Cancer"
- 04/2010 AACR Annual Meeting, VisualSonics User's Meeting, Washington DC, "Imaging Drug Delivery in Pancreatic Cancer"
- 03/2010 New York Academy of Science Hedgehog Pathway Meeting, 7 World Trade Center, New York

"Therapeutic Intervention Targeting a Hedgehog-dependent Barrier to Drug Delivery in Pancreatic Cancer"